SCHEMBL700175

SCHEMBL700175

O=C(CCCl)Nc1cccc(-c2ccc(C=C3C(=O)Nc4ccccc43)o2)c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 10/20 0.63
▸ POLB P06746 2/20 0.50
▸ PIM2 Q9P1W9 8/20 0.49
▸ DYRK1A Q13627 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ FLT3 P36888 2/20 0.44
▸ PIM3 Q86V86 1/20 0.43
▸ TLK2 Q86UE8 1/20 0.43
▸ PTPN1 P18031 2/20 0.42
▸ PAK1 Q13153 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ PLK4 O00444 1/20 0.41
▸ PLK1 P53350 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700174 1.00 PIM1 (0.63) PIM1POLBPIM2DYRK1AMEN1
SCHEMBL10091870 0.93 PIM1 (0.63) PIM1POLBPIM2DYRK1AMEN1
SCHEMBL10091711 0.88 PIM1 (0.59) PIM1POLBPIM2DYRK1AMEN1
SCHEMBL700484 0.86 PIM1 (0.69) PIM1PIM2FLT3PIM3PAK1
SCHEMBL700483 0.86 PIM1 (0.69) PIM1PIM2FLT3PIM3PAK1
SCHEMBL10091713 0.85 PIM1 (0.60) PIM1POLBPIM2DYRK1AMEN1
SCHEMBL10091712 0.84 PIM1 (0.67) PIM1POLBPIM2FLT3PIM3
SCHEMBL700067 0.81 PIM1 (0.62) PIM1POLBPIM2DYRK1AMEN1
SCHEMBL700065 0.81 PIM1 (0.62) PIM1POLBPIM2DYRK1AMEN1
SCHEMBL700066 0.81 PIM1 (0.62) PIM1POLBPIM2DYRK1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 — — US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 — — US disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 — — EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 — — US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885POLB 2906/4885PIM2 3/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885POLB 2906/4885PIM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback